Clinicopathological Characteristics and Therapeutic Response to Concurrent Chemoradiotherapy in Stage IIB–IVA Cervical Cancer

Objectives: This study aimed to describe the response to concurrent chemoradiotherapy in stage IIB–IVA cervical cancer and its association with histopathological subtype, age, stage, and tumor size.Methods: This retrospective analytical cross-sectional study reviewed the records of 109 women who completed external beam radiotherapy, intracavitary brachytherapy, and weekly cisplatin at Al Ihsan Regional General Hospital, West Java, from 2022 to 2024. Response was assessed approximately three months after treatment using the Response Evaluation Criteria in Solid Tumors version 1.1. Histopathological subtype was analyzed using the Fisher–Freeman–Halton exact test, whereas age, stage, and tumor size were analyzed using Spearman rank correlation.Results: Complete response occurred in 77.1% of women, partial response in 18.3%, stable disease in 3.7%, and progressive disease in 0.9%. Complete response rates were 77.3% in squamous cell carcinoma (80.7% of women), 82.4% in adenocarcinoma, and 50.0% in adenosquamous carcinoma (4 women). Complete response rates were 84.6% in stage IIB and 73.8% in stage IIIB; these two stages together comprised 95.4% of women. No variable was significantly associated with response (all p > 0.05).Conclusion: Most women achieved a complete response after concurrent chemoradiotherapy. Response was not significantly associated with histopathological subtype, age, stage, or tumor size, although the small number of non-squamous and stage IVA cases limits this finding. Larger prospective studies are needed.Karakteristik Klinikopatologis dan Respons Terapi Kemoradiasi Konkuren pada Kanker Serviks Stadium IIB–IVAAbstrakTujuan: Penelitian ini bertujuan menggambarkan respons kemoradiasi konkuren pada kanker serviks stadium IIB–IVA serta hubungannya dengan jenis histopatologi, usia, stadium, dan ukuran tumor.Metode: Penelitian analitik potong lintang retrospektif ini menelaah rekam medis 109 perempuan yang menyelesaikan radioterapi eksterna, brakiterapi intrakaviter, dan sisplatin mingguan di Rumah Sakit Umum Daerah Al Ihsan, Jawa Barat, pada tahun 2022–2024. Respons dinilai kurang lebih tiga bulan setelah terapi menggunakan Response Evaluation Criteria in Solid Tumors versi 1.1. Jenis histopatologi dianalisis dengan uji eksak Fisher–Freeman–Halton, sedangkan usia, stadium, dan ukuran tumor dianalisis dengan uji korelasi peringkat Spearman.Hasil: Respons komplet terjadi pada 77,1% perempuan, respons parsial 18,3%, penyakit stabil 3,7%, dan penyakit progresif 0,9%. Karsinoma sel skuamosa paling banyak ditemukan (80,7%). Angka respons komplet adalah 77,3% pada karsinoma sel skuamosa, 82,4% pada adenokarsinoma, dan 50,0% pada karsinoma adenoskuamosa (4 perempuan). Respons komplet sebesar 84,6% pada stadium IIB dan 73,8% pada stadium IIIB, yang bersama-sama mencakup 95,4% perempuan. Tidak ada variabel yang berhubungan bermakna dengan respons (seluruh p > 0,05).Kesimpulan: Sebagian besar perempuan mencapai respons komplet setelah kemoradiasi konkuren. Respons tidak berhubungan bermakna dengan jenis histopatologi, usia, stadium, maupun ukuran tumor, meskipun jumlah kasus nonskuamosa dan stadium IVA yang sedikit membatasi temuan ini. Diperlukan penelitian prospektif dengan jumlah sampel yang lebih besar.

Authors

Institutions

Publication Details

Journal
Indonesian Journal of Obstetrics & Gynecology Science
Published
2026-11-16
DOI
https://doi.org/10.24198/obgynia.v9i3.1294
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinicopathological Characteristics and Therapeutic Response to Concurrent Chemoradiotherapy in Stage IIB–IVA Cervical Cancer

Oky Haribudiman, Wiryawan Permadi, Niken Amalia Gandini
2 links
Indonesian Journal of Obstetrics & Gynecology Science
Endometrial and Cervical Cancer Treatments
article

Clinicopathological Characteristics and Therapeutic Response to Concurrent Chemoradiotherapy in Stage IIB–IVA Cervical Cancer

Oky Haribudiman, Wiryawan Permadi, Niken Amalia Gandini
article en

Abstract

Objectives: This study aimed to describe the response to concurrent chemoradiotherapy in stage IIB–IVA cervical cancer and its association with histopathological subtype, age, stage, and tumor size.Methods: This retrospective analytical cross-sectional study reviewed the records of 109 women who completed external beam radiotherapy, intracavitary brachytherapy, and weekly cisplatin at Al Ihsan Regional General Hospital, West Java, from 2022 to 2024. Response was assessed approximately three months after treatment using the Response Evaluation Criteria in Solid Tumors version 1.1. Histopathological subtype was analyzed using the Fisher–Freeman–Halton exact test, whereas age, stage, and tumor size were analyzed using Spearman rank correlation.Results: Complete response occurred in 77.1% of women, partial response in 18.3%, stable disease in 3.7%, and progressive disease in 0.9%. Complete response rates were 77.3% in squamous cell carcinoma (80.7% of women), 82.4% in adenocarcinoma, and 50.0% in adenosquamous carcinoma (4 women). Complete response rates were 84.6% in stage IIB and 73.8% in stage IIIB; these two stages together comprised 95.4% of women. No variable was significantly associated with response (all p > 0.05).Conclusion: Most women achieved a complete response after concurrent chemoradiotherapy. Response was not significantly associated with histopathological subtype, age, stage, or tumor size, although the small number of non-squamous and stage IVA cases limits this finding. Larger prospective studies are needed.Karakteristik Klinikopatologis dan Respons Terapi Kemoradiasi Konkuren pada Kanker Serviks Stadium IIB–IVAAbstrakTujuan: Penelitian ini bertujuan menggambarkan respons kemoradiasi konkuren pada kanker serviks stadium IIB–IVA serta hubungannya dengan jenis histopatologi, usia, stadium, dan ukuran tumor.Metode: Penelitian analitik potong lintang retrospektif ini menelaah rekam medis 109 perempuan yang menyelesaikan radioterapi eksterna, brakiterapi intrakaviter, dan sisplatin mingguan di Rumah Sakit Umum Daerah Al Ihsan, Jawa Barat, pada tahun 2022–2024. Respons dinilai kurang lebih tiga bulan setelah terapi menggunakan Response Evaluation Criteria in Solid Tumors versi 1.1. Jenis histopatologi dianalisis dengan uji eksak Fisher–Freeman–Halton, sedangkan usia, stadium, dan ukuran tumor dianalisis dengan uji korelasi peringkat Spearman.Hasil: Respons komplet terjadi pada 77,1% perempuan, respons parsial 18,3%, penyakit stabil 3,7%, dan penyakit progresif 0,9%. Karsinoma sel skuamosa paling banyak ditemukan (80,7%). Angka respons komplet adalah 77,3% pada karsinoma sel skuamosa, 82,4% pada adenokarsinoma, dan 50,0% pada karsinoma adenoskuamosa (4 perempuan). Respons komplet sebesar 84,6% pada stadium IIB dan 73,8% pada stadium IIIB, yang bersama-sama mencakup 95,4% perempuan. Tidak ada variabel yang berhubungan bermakna dengan respons (seluruh p > 0,05).Kesimpulan: Sebagian besar perempuan mencapai respons komplet setelah kemoradiasi konkuren. Respons tidak berhubungan bermakna dengan jenis histopatologi, usia, stadium, maupun ukuran tumor, meskipun jumlah kasus nonskuamosa dan stadium IVA yang sedikit membatasi temuan ini. Diperlukan penelitian prospektif dengan jumlah sampel yang lebih besar.

Indonesian Journal of Obstetrics & Gynecology ScienceVol. 9(3)
Dr. Hasan Sadikin General Hospital (ID), Padjadjaran University (ID)
Good health and well-being
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon